A recently published patent application by Ion Torrent Systems reveals details about a potential new sequencing technology that the firm might be developing commercially.

However, it is unclear whether the company is currently developing a DNA-sequencing platform.

Ion Torrent, which has locations in Guilford, Conn., and San Francisco, was founded by Jonathan Rothberg, the founding CEO of 454 Life Sciences.

The firm has not yet talked publicly about its technology, which its website describes as "groundbreaking and highly disruptive."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.